1. Home
  2. CVAC vs KRP Comparison

CVAC vs KRP Comparison

Compare CVAC & KRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVAC
  • KRP
  • Stock Information
  • Founded
  • CVAC 2000
  • KRP 2013
  • Country
  • CVAC Germany
  • KRP United States
  • Employees
  • CVAC N/A
  • KRP N/A
  • Industry
  • CVAC Biotechnology: Pharmaceutical Preparations
  • KRP Oil & Gas Production
  • Sector
  • CVAC Health Care
  • KRP Energy
  • Exchange
  • CVAC Nasdaq
  • KRP Nasdaq
  • Market Cap
  • CVAC 1.2B
  • KRP 1.2B
  • IPO Year
  • CVAC 2020
  • KRP 2017
  • Fundamental
  • Price
  • CVAC $5.36
  • KRP $12.84
  • Analyst Decision
  • CVAC Hold
  • KRP Hold
  • Analyst Count
  • CVAC 3
  • KRP 5
  • Target Price
  • CVAC $6.83
  • KRP $17.20
  • AVG Volume (30 Days)
  • CVAC 411.0K
  • KRP 397.4K
  • Earning Date
  • CVAC 11-11-2025
  • KRP 11-06-2025
  • Dividend Yield
  • CVAC N/A
  • KRP 13.38%
  • EPS Growth
  • CVAC N/A
  • KRP N/A
  • EPS
  • CVAC 1.01
  • KRP N/A
  • Revenue
  • CVAC $599,540,810.00
  • KRP $312,566,668.00
  • Revenue This Year
  • CVAC N/A
  • KRP $9.22
  • Revenue Next Year
  • CVAC $23.83
  • KRP $2.47
  • P/E Ratio
  • CVAC $5.34
  • KRP N/A
  • Revenue Growth
  • CVAC 675.15
  • KRP N/A
  • 52 Week Low
  • CVAC $2.37
  • KRP $10.98
  • 52 Week High
  • CVAC $5.72
  • KRP $16.99
  • Technical
  • Relative Strength Index (RSI)
  • CVAC 45.73
  • KRP 36.77
  • Support Level
  • CVAC $5.34
  • KRP $12.80
  • Resistance Level
  • CVAC $5.41
  • KRP $13.17
  • Average True Range (ATR)
  • CVAC 0.04
  • KRP 0.26
  • MACD
  • CVAC -0.00
  • KRP -0.06
  • Stochastic Oscillator
  • CVAC 18.18
  • KRP 12.60

About CVAC CureVac N.V.

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.

About KRP Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

Share on Social Networks: